Tempest Therapeutics is a clinical-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. Tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. The molecules were developed by Inception Sciences, a Versant Ventures affiliated drug discovery engine. Tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. Tempest is backed by a syndicate of leading US and China based venture capital firms.